Terms: = Breast cancer AND CEP17 AND Clinical Outcome
9 results:
1. clinical and Pathologic Features Associated With Invasive breast Carcinoma With 2018 American Society of clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [cep17] Ratio ≥2.0 and Average HER2 Copy Number <4.0).
Hoda RS; Zarei S; McIntire PJ; Sprague C; Mekhail Y; Carlson DL; Komforti MK; Downs-Kelly EP
Arch Pathol Lab Med; 2022 Jun; 146(6):701-709. PubMed ID: 34559875
[TBL] [Abstract] [Full Text] [Related]
2. Centromere 17 copy number gain reflects chromosomal instability in breast cancer.
Lee K; Kim HJ; Jang MH; Lee S; Ahn S; Park SY
Sci Rep; 2019 Nov; 9(1):17968. PubMed ID: 31784614
[TBL] [Abstract] [Full Text] [Related]
3. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
Halilovic A; Verweij DI; Simons A; Stevens-Kroef MJPL; Vermeulen S; Elsink J; Tops BBJ; Otte-Höller I; van der Laak JAWM; van de Water C; Boelens OBA; Schlooz-Vries MS; Dijkstra JR; Nagtegaal ID; Tol J; van Cleef PHJ; Span PN; Bult P
Sci Rep; 2019 Aug; 9(1):11679. PubMed ID: 31406196
[TBL] [Abstract] [Full Text] [Related]
4. HER2/cep17 Ratios and clinical outcome in HER2-Positive Early breast cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract] [Full Text] [Related]
5. HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.
Zabaglo L; Stoss O; Rüschoff J; Zielinski D; Salter J; Arfi M; Bradbury I; Dafni U; Piccart-Gebhart M; Procter M; Dowsett M;
Ann Oncol; 2013 Nov; 24(11):2761-6. PubMed ID: 23894039
[TBL] [Abstract] [Full Text] [Related]
6. HER2/cep17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract] [Full Text] [Related]
7. Droplet Digital™ PCR quantitation of HER2 expression in FFPE breast cancer samples.
Heredia NJ; Belgrader P; Wang S; Koehler R; Regan J; Cosman AM; Saxonov S; Hindson B; Tanner SC; Brown AS; Karlin-Neumann G
Methods; 2013 Jan; 59(1):S20-3. PubMed ID: 23036330
[TBL] [Abstract] [Full Text] [Related]
8. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.
Schlüter B; Gerhards R; Strumberg D; Voigtmann R
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1389-400. PubMed ID: 20217132
[TBL] [Abstract] [Full Text] [Related]
9. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Dowsett M; Procter M; McCaskill-Stevens W; de Azambuja E; Dafni U; Rueschoff J; Jordan B; Dolci S; Abramovitz M; Stoss O; Viale G; Gelber RD; Piccart-Gebhart M; Leyland-Jones B
J Clin Oncol; 2009 Jun; 27(18):2962-9. PubMed ID: 19364966
[TBL] [Abstract] [Full Text] [Related]
